CLINDAMYCIN INJECTION IN 5% DEXTROSE SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

CLINDAMYCIN (CLINDAMYCIN PHOSPHATE)

から入手可能:

BAXTER CORPORATION

ATCコード:

J01FF01

INN（国際名）:

CLINDAMYCIN

投薬量:

300MG

医薬品形態:

SOLUTION

構図:

CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 300MG

投与経路:

INTRAVENOUS

パッケージ内のユニット:

100

処方タイプ:

Prescription

治療領域:

LINCOMYCINS

製品概要:

Active ingredient group (AIG) number: 0105830008; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2023-03-02

製品の特徴

_Clindamycin Injection in 5% Dextrose_
_Page 1 of 33 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CLINDAMYCIN INJECTION IN 5% DEXTROSE
Ready-to-use bags, clindamycin 6 mg / mL (300 mg / 50 mL), 12 mg / mL
(600 mg /
50 mL) and
18 mg / mL (900 mg / 50 mL) (as clindamycin phosphate)
STERILE SOLUTION
ANTIBIOTIC
Baxter Corporation
7125 Mississauga Road
Mississauga, Ontario
L5N 0C2
Date of Revision:
February 1, 2019
Submission Control No: 212923
Baxter and GALAXY are trademarks of Baxter International Inc.
_Clindamycin Injection in 5% Dextrose_
_Page 2 of 33 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
5
WARNINGS AND PRECAUTIONS
....................................................................................
5
ADVERSE REACTIONS
......................................................................................................
8
DRUG INTERACTIONS
....................................................................................................
10
DOSAGE AND ADMINISTRATION
................................................................................
11
OVERDOSAGE
...................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 13
STORAGE AND STABILITY
............................................................................................
15
SPECIAL HANDLING INSTRUCTIONS
.........................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 16